Classification of thyroid hormone receptor agonists and antagonists using statistical learning approaches

In silico models are presented for modeling and predicting thyroid hormone receptor (TR) agonists and antagonists. A data set consisting of 258 compounds is used in the present work. The C4.5, random forest (RF) and support vector machine (SVM) statistical methods were used for evaluation. The performance of the quantitative structure–activity relationships was further validated with fivefold cross-validation and an independent external test set. The C4.5 model is slightly weak, and the prediction accuracies of the agonists and antagonists are 93.2 and 57.8% for cross-validation, respectively, averaging 83.1% of correctly classified compounds in the test set. The RF model possesses an average prediction accuracy of 84.0 and 87.1% for the cross-validation and external validation, respectively. Furthermore, the overall prediction accuracy and the external prediction accuracy are 96.6 and 97.2%, respectively, for the SVM model. The results would validate the reliability of the derived models, further demonstrating that RF and SVM models are useful tools capable of classifying TR-binding ligands as agonists or antagonists.

[1]  M. Erion,et al.  Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs. , 2008, Journal of medicinal chemistry.

[2]  J. Ross Quinlan,et al.  C4.5: Programs for Machine Learning , 1992 .

[3]  Ifedayo Victor Ogungbe,et al.  (−) Arctigenin and (+) Pinoresinol Are Antagonists of the Human Thyroid Hormone Receptor β , 2014, J. Chem. Inf. Model..

[4]  Ruben Abagyan,et al.  Discovery of diverse thyroid hormone receptor antagonists by high-throughput docking , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Na Li,et al.  Dibutyl phthalate contributes to the thyroid receptor antagonistic activity in drinking water processes. , 2010, Environmental science & technology.

[6]  Peter Cornelius,et al.  Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TR beta subtype-selective thyromimetics. , 2003, Bioorganic & medicinal chemistry letters.

[7]  Yonghua Wang,et al.  Structural requirements of pyrimidine, thienopyridine and ureido thiophene carboxamide-based inhibitors of the checkpoint kinase 1: QSAR, docking, molecular dynamics analysis , 2012, Journal of Molecular Modeling.

[8]  Ruili Huang,et al.  Identification of Thyroid Hormone Receptor Active Compounds Using a Quantitative High-Throughput Screening Platform , 2014, Current chemical genomics and translational medicine.

[9]  Wei Yang,et al.  Structure-based approach for the study of thyroid hormone receptor binding affinity and subtype selectivity , 2016, Journal of biomolecular structure & dynamics.

[10]  Johan Malm,et al.  Thyroid receptor ligands. Part 5: novel bicyclic agonist ligands selective for the thyroid hormone receptor beta. , 2006, Bioorganic & medicinal chemistry letters.

[11]  Vladimir Vapnik,et al.  An overview of statistical learning theory , 1999, IEEE Trans. Neural Networks.

[12]  Thomas S. Scanlan,et al.  Design of thyroid hormone receptor antagonists from first principles , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[13]  Steven Salzberg,et al.  Programs for Machine Learning , 2004 .

[14]  Yan Li,et al.  In silico Prediction of Androgenic and Nonandrogenic Compounds Using Random Forest , 2009 .

[15]  R. Joffe Hormone treatment of depression , 2011, Dialogues in clinical neuroscience.

[16]  Fangfang Wang,et al.  Development of in silico models for pyrazoles and pyrimidine derivatives as cyclin-dependent kinase 2 inhibitors. , 2011, Journal of molecular graphics & modelling.

[17]  Peter Brandt,et al.  Thyroid receptor ligands. 6. A high affinity "direct antagonist" selective for the thyroid hormone receptor. , 2006, Journal of medicinal chemistry.

[18]  Esa Alhoniemi,et al.  Clustering of the self-organizing map , 2000, IEEE Trans. Neural Networks Learn. Syst..

[19]  A. Murk,et al.  T-screen to quantify functional potentiating, antagonistic and thyroid hormone-like activities of poly halogenated aromatic hydrocarbons (PHAHs). , 2006, Toxicology in vitro : an international journal published in association with BIBRA.

[20]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[21]  B. Biondi,et al.  Thyroid and obesity: an intriguing relationship. , 2010, The Journal of clinical endocrinology and metabolism.

[22]  Mevlut Ture,et al.  Using Kaplan-Meier analysis together with decision tree methods (C&RT, CHAID, QUEST, C4.5 and ID3) in determining recurrence-free survival of breast cancer patients , 2009, Expert Syst. Appl..

[23]  Robert P. Sheridan,et al.  Random Forest: A Classification and Regression Tool for Compound Classification and QSAR Modeling , 2003, J. Chem. Inf. Comput. Sci..

[24]  G. Ness,et al.  Transcriptional regulation of rat hepatic low-density lipoprotein receptor and cholesterol 7 alpha hydroxylase by thyroid hormone. , 1995, Archives of biochemistry and biophysics.

[25]  G. Durst,et al.  Design and synthesis of a novel series of [1-(4-hydroxy-benzyl)-1H-indol-5-yloxy]-acetic acid compounds as potent, selective, thyroid hormone receptor β agonists. , 2015, Bioorganic & medicinal chemistry letters.

[26]  A. Engle,et al.  Synthesis and structure-activity relationships of oxamic acid and acetic acid derivatives related to L-thyronine. , 1995, Journal of medicinal chemistry.

[27]  Steven L. Salzberg,et al.  Book Review: C4.5: Programs for Machine Learning by J. Ross Quinlan. Morgan Kaufmann Publishers, Inc., 1993 , 1994, Machine Learning.

[28]  J. Baxter,et al.  Hammett analysis of selective thyroid hormone receptor modulators reveals structural and electronic requirements for hormone antagonists. , 2005, Journal of the American Chemical Society.

[29]  R. Fletterick,et al.  Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist. , 2002, Endocrinology.

[30]  W. Singer,et al.  Thyroid hormone treatment of depression. , 1995, Thyroid : official journal of the American Thyroid Association.

[31]  Minsheng Zhang,et al.  Thyroid receptor ligands. Part 8: Thyromimetics derived from N-acylated-alpha-amino acid derivatives displaying modulated pharmacological selectivity compared with KB-141. , 2007, Bioorganic & medicinal chemistry letters.

[32]  Roberto Todeschini,et al.  Handbook of Molecular Descriptors , 2002 .

[33]  L. Ye,et al.  Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1. , 2003, Journal of medicinal chemistry.

[34]  Johan Malm,et al.  Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor β subtype selective agonist KB-141 , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[35]  David Ward,et al.  Comparison of statistical methods for classification of ovarian cancer using mass spectrometry data , 2003, Bioinform..

[36]  Á. Pascual,et al.  Thyroid hormone receptors, cell growth and differentiation. , 2013, Biochimica et biophysica acta.

[37]  H. Kagechika,et al.  Novel thyroid hormone receptor antagonists with an N-alkylated diphenylamine skeleton. , 2007, Bioorganic & medicinal chemistry.

[38]  W. Dillmann Editorial: thyroid hormone action and cardiac contractility - a complex affair. , 1996, Endocrinology.

[39]  Katherine A. Drake,et al.  Design and synthesis of complementing ligands for mutant thyroid hormone receptor TRβ(R320H): a tailor-made approach toward the treatment of resistance to thyroid hormone , 2005 .

[40]  Teuvo Kohonen,et al.  Self-Organizing Maps , 2010 .

[41]  Hua Yu,et al.  A Novel Chemometric Method for the Prediction of Human Oral Bioavailability , 2012, International journal of molecular sciences.

[42]  M. D. de Gooyer,et al.  Mechanism of action of a nanomolar potent, allosteric antagonist of the thyroid‐stimulating hormone receptor , 2012, British journal of pharmacology.

[43]  Bernard F. Buxton,et al.  Drug Design by Machine Learning: Support Vector Machines for Pharmaceutical Data Analysis , 2001, Comput. Chem..

[44]  Thyroid receptor ligands. Part 7: Indirect antagonists of the thyroid hormone receptor with improved affinity. , 2007, Bioorganic & medicinal chemistry letters.

[45]  Johan Malm,et al.  Thyroid receptor ligands. Part 4: 4'-amido bioisosteric ligands selective for the thyroid hormone receptor beta. , 2006, Bioorganic & medicinal chemistry letters.

[46]  J. Stepan,et al.  Biochemical assessment of bone loss in patients on long-term thyroid hormone treatment. , 1992, Bone and Mineral.

[47]  Hongmao Sun Predicting ADMET Properties by Projecting onto Chemical Space?Benefits and Pitfalls , 2005 .

[48]  Z. R. Li,et al.  Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. , 2006, Journal of molecular graphics & modelling.

[49]  J. Baxter,et al.  A designed antagonist of the thyroid hormone receptor. , 2001, Bioorganic & medicinal chemistry letters.

[50]  S. So,et al.  Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia. , 2014, Journal of medicinal chemistry.

[51]  J. Marugan,et al.  A selective TSH receptor antagonist inhibits stimulation of thyroid function in female mice. , 2014, Endocrinology.

[52]  Johan Malm,et al.  Thyroid receptor ligands. Part 2: Thyromimetics with improved selectivity for the thyroid hormone receptor beta. , 2004, Bioorganic & medicinal chemistry letters.

[53]  R. L. Dow,et al.  Thyroid receptor agonists for the treatment of androgenetic alopecia. , 2010, Bioorganic & medicinal chemistry letters.

[54]  P. Ladenson,et al.  Thyroid hormone antagonists: potential medical applications and structure activity relationships. , 2009, Current medicinal chemistry.

[55]  H. Gronemeyer,et al.  Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. , 2000, Trends in pharmacological sciences.

[56]  B. Rubin,et al.  Bisphenol A: An endocrine disruptor with widespread exposure and multiple effects , 2011, The Journal of Steroid Biochemistry and Molecular Biology.

[57]  Vincent Laudet,et al.  Principles for modulation of the nuclear receptor superfamily , 2004, Nature Reviews Drug Discovery.

[58]  K. Nakao,et al.  Thyroid hormone action is disrupted by bisphenol A as an antagonist. , 2002, The Journal of clinical endocrinology and metabolism.

[59]  H. Gronemeyer,et al.  Transcription factors 3: nuclear receptors. , 1995, Protein profile.

[60]  C Helma,et al.  Fragment generation and support vector machines for inducing SARs , 2002, SAR and QSAR in environmental research.

[61]  S. Mandrup,et al.  Molecular basis for gene-specific transactivation by nuclear receptors. , 2011, Biochimica et biophysica acta.

[62]  Katherine A. Drake,et al.  Design and synthesis of complementing ligands for mutant thyroid hormone receptor TRbeta(R320H): a tailor-made approach toward the treatment of resistance to thyroid hormone. , 2005, Bioorganic & medicinal chemistry.